A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of the study is to determine whether the topical application of BRT-FC-83C is effective in the treatment of mild to moderate atopic dermatitis.
Condition or disease
Atopic dermatitis is a common skin disease. BRT-FC-83C is a skin cream that does not contain corticosteroids or other anti-inflammatory components. It represents a novel class of skin barrier repair therapy for chronic dermatoses. The objective of this clinical study is to determine whether BRT-FC-83C, applied twice a day to the affected area of the skin, ameliorates signs and symptoms of mild to moderate atopic dermatitis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinically verified mild to moderate atopic dermatitis. Atopy diagnosis based on clinical scores of 3-7.5 based on the Rajka and Langeland criteria
Men or women ages 18-50 years
At least one mild to moderate atopic lesion involving no more than 20% Body Surface Area (BSA)
Active atopic dermatitis for at least 3 years
Willingness to cooperate and participate by following study requirements
Written informed consent
Individuals with actively oozing atopic lesions
Individuals who are smokers
Individuals with insulin-dependent diabetes mellitus
Individuals that are known to be pregnant, nursing, or planning to become pregnant within the next six months after enrollment
Individuals currently participating in another clinical usage study that would interfere with this study